Skip to main content
. 2020 Dec 31;71(1):34–42. doi: 10.1136/gutjnl-2020-322339

Table 4A.

Type of treatment escalation in the FL-IFX treatment group within 52 weeks

Number of patients needing treatment escalation in the FL-IFX group, per-treatment escalation type
Continuation of IFX after five infusions; n (%) 12/49 (24.5)
Restart anti-TNF therapy; n (%) 7/49 (14.5)
 Infliximab; n 6
 Adalimumab; n 1
Corticosteroid course; n (%) 2/49 (4)

FL-IFX, first-line infliximab; TNF, tumour necrosis factor.